117 related articles for article (PubMed ID: 17695700)
1. [Antihypertensive therapy and cardiovascular prevention. The role of angiotensin II receptor blockers].
Verdecchia P; Cavallini C; Angeli F; Andreani F; Garofoli M; Reboldi GP; Ambrosio G
G Ital Cardiol (Rome); 2007 Aug; 8(8):491-7. PubMed ID: 17695700
[TBL] [Abstract][Full Text] [Related]
2. Do angiotensin II receptor blockers increase the risk of myocardial infarction?
Verdecchia P; Angeli F; Gattobigio R; Reboldi GP
Eur Heart J; 2005 Nov; 26(22):2381-6. PubMed ID: 16081468
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
[TBL] [Abstract][Full Text] [Related]
4. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
7. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
[TBL] [Abstract][Full Text] [Related]
8. Have angiotensin receptor blockers lived up to expectations?
Fitchett D
Can J Cardiol; 2005 May; 21(7):569-75. PubMed ID: 15940354
[TBL] [Abstract][Full Text] [Related]
9. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
[TBL] [Abstract][Full Text] [Related]
10. Effect of angiotensin receptor blockers in the prevention of type 2 diabetes and cardiovascular events: a meta-analysis of randomized trials.
Song HF; Wang S; Li HW
Chin Med J (Engl); 2012 May; 125(10):1804-10. PubMed ID: 22800904
[TBL] [Abstract][Full Text] [Related]
11. Evidence for the efficacy of ARBs across the cardiovascular continuum.
Gupta M; Honos GN; Velazquez EJ; Chung N; Oigman W; Maggioni AP
Curr Med Res Opin; 2010 May; 26(5):1203-18. PubMed ID: 20302552
[TBL] [Abstract][Full Text] [Related]
12. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
[TBL] [Abstract][Full Text] [Related]
13. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
[TBL] [Abstract][Full Text] [Related]
14. Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials.
Flaa A; Aksnes TA; Strand A; Kjeldsen SE
Expert Rev Cardiovasc Ther; 2007 May; 5(3):451-61. PubMed ID: 17489670
[TBL] [Abstract][Full Text] [Related]
15. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
16. ARBs and Myocardial Infarction.
Med Lett Drugs Ther; 2005 May; 47(1208):38-9. PubMed ID: 15880086
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor blockers and cerebral protection in stroke.
Thöne-Reineke C; Steckelings UM; Unger T
J Hypertens Suppl; 2006 Mar; 24(1):S115-21. PubMed ID: 16601564
[TBL] [Abstract][Full Text] [Related]
18. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
19. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients.
Costanzo P; Perrone-Filardi P; Petretta M; Marciano C; Vassallo E; Gargiulo P; Paolillo S; Petretta A; Chiariello M
J Hypertens; 2009 Jun; 27(6):1136-51. PubMed ID: 19451836
[TBL] [Abstract][Full Text] [Related]
20. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial.
Maione A; Nicolucci A; Craig JC; Tognoni G; Moschetta A; Palasciano G; Pugliese G; Procaccini DA; Gesualdo L; Pellegrini F; Strippoli GF;
J Nephrol; 2007; 20(6):646-55. PubMed ID: 18046666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]